Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nancy Labastida-Mercado is active.

Publication


Featured researches published by Nancy Labastida-Mercado.


Hematology/Oncology and Stem Cell Therapy | 2015

The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms

Nancy Labastida-Mercado; Samantha Galindo-Becerra; Javier Garcés-Eisele; Perla R. Colunga-Pedraza; Valeria Guzman-Olvera; Virginia Reyes-Núñez; Guillermo J. Ruiz-Delgado; Guillermo J. Ruiz-Argüelles

CONTEXT AND OBJECTIVE By using molecular markers, it is possible to gain information on both the classification and etiopathogenesis of chronic myeloproliferative neoplasias (MPN). METHODS In a group of 27 Mexican mestizo patients with MPNs, we studied seven molecular markers: the BCR/ABL1 fusion gene, the JAK2 V617F mutation, the JAK2 exon 12 mutations, the MPL W515L mutation, the MPL W515K mutation, and the calreticulin (CALR) exon 9 deletion or insertion. Patients with the BCR/ABL1 fusion gene were excluded. We studied 14 patients with essential thrombocythemia (ET), eight with polycythemia vera (PV), four with primary myelofibrosis (MF), and one with undifferentiated MPN. RESULTS We found twelve individuals with the JAK2 V617F mutation; five of them had been clinically classified as PV, five as ET, and one as MF. One patient with the MPL W515L was identified with a clinical picture of ET. Five patients with the CALR mutation were identified, four ET and one MF. No individuals with either the MPL W515K mutation or the JAK2 exon 12 mutations were identified. The most consistent relationship was that between PV and the JAK2 V617F mutation (p=.01). CONCLUSIONS Despite its small size, the study shows much less prevalence of JAK2 mutation in PV, ET and MF, which does not match international data.


Bone Marrow Transplantation | 2015

Publications of bone marrow transplants in Latin America. A report of the Latin American Group of Bone Marrow Transplantation

Guillermo J. Ruiz-Argüelles; V Abello-Polo; C Arrais-Rodrígues; L.F.S. Bouzas; C.C. de Souza; G Dufort; R Gabus; Laura Samantha Galindo-Becerra; David Gómez-Almaguer; N Hammerschlak; J C Jaime-Fagundo; Gregorio Jaimovich; A J Karduss-Urueta; Nancy Labastida-Mercado; M Nese; R. Pasquini; Adriana Seber

Publications of bone marrow transplants in Latin America. A report of the Latin American Group of Bone Marrow Transplantation


Bone Marrow Transplantation | 2018

Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas

Amado Kardduss-Urueta; Robert Peter Gale; César Homero Gutiérrez-Aguirre; Miguel Angel Herrera-Rojas; Iván Murrieta-Álvarez; Rosendo Perez-Fontalvo; Guillermo J. Ruiz-Delgado; Giovanni Ruiz-Rojas; Gregorio Jaimovich; Leonardo Feldman; Nancy Labastida-Mercado; Alicia Endara; Martin Castro; Samantha Galindo-Becerra; María Angélica Cardona-Molina; David Gómez-Almaguer; Guillermo J. Ruiz-Argüelles

We studied rates of granulocyte and platelets recovery in 359 consecutive subjects receiving blood cell infusions in the context of autotransplants for plasma cell myeloma (N = 216) and lymphomas (N = 143). Blood cells were mobilised with filgrastim given for 4–5 days and collected after a median of 2 (range, 1–2) apheresis. Apheresis products were stored at 4° C for a median of 3 days (range, 2–6 days). Most subjects received carmustine, etoposide, cytarabine and melphalan (BEAM), cyclophosphamide, carmustine and etoposide (CBV) or high-dose melphalan. Filgrastim was given post transplant to 319 subjects. Median numbers of mononuclear cells collected was 31 × 10E + 6/kg (interquartile range (IQR) 37 × 10E + 6 cells/kg). Median numbers of CD34-positive cells collected was 3.6 × 10E + 6/kg (IQR 3.8 × 10E + 6/Kg). Median viability after collection was 90% (IQR 7%) after storage, 88% (IQR 12%). A total of 255 of 256 evaluable subjects recovered bone marrow function and there was no late bone marrow failure. Median interval to neutrophils >0.5 × E + 9/L was 13 days (range, 9–39 days) and to platelets >20 × 10E + 9/L, 16 days (range, 7–83 days). These rates and ranges seem comparable to those reported after autotransplants of frozen blood cells. There was no correlation between numbers of storage days at 4 °C and viability afte storage (r = −0.018, p = 0.14)) nor rates of recovery of neutrophils (r = −0.054, p = 0.52) or platelets (r = 0.116, p = 0.14). Blood cells collected for autotransplant can be stored at 4 °C for 6 d. This method is simple, inexpensive and widely applicable.


Acta Haematologica | 2015

Outcome of Recipients of Hematopoietic Stem Cell Transplants Who Require Intensive Care Unit Support: A Single Institution Experience

Samantha Galindo-Becerra; Nancy Labastida-Mercado; Jaime Rosales-Padrón; Jessica García-Chavez; Elena Soto-Vega; Liliana Rivadeneyra-Espinoza; Andrés A León-Peña; Danitza Fernández-Lara; Mónica Domínguez-Cid; Javier Anthon-Méndez; Daniel Arizpe-Bravo; Guillermo J. Ruiz-Delgado; Guillermo J. Ruiz-Argüelles

Admission to the intensive care unit (ICU) of a patient who has been grafted with hematopoietic stem cells is a serious event, but the role of the ICU in this setting remains controversial. Data were analyzed from patients who underwent autologous or allogeneic bone marrow transplantation at the Centro de Hematología y Medicina Interna de Puebla, México, between May 1993 and October 2014. In total, 339 patients were grafted: 150 autografts and 189 allografts; 68 of the grafted patients (20%) were admitted to the ICU after transplantation: 27% of the allografted and 11% of the autografted patients (p = 0.2). Two of 17 autografted patients (12%) and 5 of 51 allografted patients (10%) survived. All patients who required insertion of an endotracheal tube died, whereas 7 of 11 patients without invasive mechanical ventilation survived (p = 0.001). Only 10% of the grafted patients survived their stay in the ICU; this figure is lower than those reported from other centers and may reflect several facts, varying from the quality of the ICU support to ICU admission criteria to the initial management of all the grafts in an outpatient setting, which could somehow delay the arrival of patients to the hospital.


Hematology | 2015

Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: The Mexican experience

Alejandro Schcolnik-Cabrera; Nancy Labastida-Mercado; Laura Samantha Galindo-Becerra; David Gómez-Almaguer; Miguel Angel Herrera-Rojas; Guillermo J. Ruiz-Delgado; Guillermo J. Ruiz-Argüelles

Abstract Background Paroxysmal nocturnal haemoglobinuria (PNH) presents as two major entities: the classical form, predominantly haemolytic and a secondary type with marrow failure and resultant aplastic anaemia (AA-PNH). Currently, the treatment of choice of the haemolytic variant is eculizumab; however, the most frequent form of PNH in México is AA-PNH. Patients and methods Six consecutive AA-PNH patients with HLA-identical siblings were allografted in two institutions in México, employing a reduced-intensity conditioning regimen for stem cell transplantation (RIST) conducted on an outpatient basis. Results Median age of the patients was 37 years (range 25–48). The patients were given a median of 5.4 × 106/kg allogeneic CD34(+) cells, using 1–3 apheresis procedures. Median time to achieve above 0.5 × 109/l granulocytes was 21 days, whereas median time to achieve above 20 × 109/l platelets was 17 days. Five patients are alive for 330–3150 days (median 1437) after the allograft. The 3150-day overall survival is 83.3%, whereas median survival has not been reached, being above 3150 days. Conclusion We have shown that hypoplastic PNH patients can be allografted safely using RIST and that the long-term results are adequate, the cost–benefit ratio of this treatment being reasonable. Additional studies are needed to confirm the usefulness of RIST in the treatment of AA-PNH.


Blood | 2014

Cell-Freezing Devices Are Not Strictly Needed to Start an Autologous Hematopoietic Transplantation Program: Non-Cryopreserved Peripheral Blood Stem Cells Can be Used to Restore Hematopoiesis after High Dose Chemotherapy: A Multicenter Experience in 268 Autografts in Patients with Multiple Myeloma or Lymphoma. Study on Behalf of the Latin-American Bone Marrow Transplantation Group (LABMT)

Amado Karduss-Urueta; Guillermo J. Ruiz-Argüelles; Rosendo Perez; Guillermo J. Ruiz-Delgado; Angelica Maria Cardona; Nancy Labastida-Mercado; Luis R Gomez; Samantha Galindo-Becerra; Pedro Reyes; Juan Alejo Jimenez


Inmunología | 2013

Antiphospholipid antibodies in Mexican HIV-positive patients

Elena Soto-Vega; Alejandro Ruiz-Argüelles; Claudia Mendoza-Pinto; Jonathan R. Hernández-Molina; José Alejandro Varela-Cabrera; María José Muñoz-Pérez; Nancy Labastida-Mercado; Mario García-Carrasco; Liliana Rivadeneyra-Espinoza; Carlos Arroyo


Biology of Blood and Marrow Transplantation | 2015

Donor Cell Leukemia: A Prospective Study of Its Identification and Treatment

Guillermo J. Ruiz-Delgado; Samantha Galindo-Becerra; Nancy Labastida-Mercado; Angélica González-Cortés; Nora Ángela Martagón-Herrera; Mónica Patricia González-Ramírez; Javier Garcés-Eisele; Alejandro Ruiz-Arguelles; Guillermo J. Ruiz-Argüelles


Biology of Blood and Marrow Transplantation | 2015

Health-Related Quality of Life in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation Employing the Mexican Reduced-Intensity Conditioning

Nancy Labastida-Mercado; Samantha Galindo-Becerra; Mónica Patricia González-Ramírez; Karla Miravete-Lagunes; Andrés Gómez-de-León; Sergio Ponce-de-León; Andrea P. Tenorio-Rojo; Nora Ángela Martagón-Herrera; Jesús Hernández-Reyes; Arturo García-Villaseñor; Esteban Burguette-Hernandez; Guillermo J. Ruiz Delgado; David Gómez-Almaguer; Guillermo J. Ruiz-Argüelles


Biology of Blood and Marrow Transplantation | 2015

Reduced-Intensity Stem Cell Allografting for PNH Patients in the Eculizumab Era: The Mexican Experience

Alejandro Schcolnik-Cabrera; Nancy Labastida-Mercado; Samantha Galindo-Becerra; David Gómez-Almaguer; Miguel Angel Herrera-Rojas; Guillermo J. Ruiz-Delgado; Guillermo J. Ruiz-Argüelles

Collaboration


Dive into the Nancy Labastida-Mercado's collaboration.

Top Co-Authors

Avatar

Guillermo J. Ruiz-Argüelles

Universidad Popular Autónoma del Estado de Puebla

View shared research outputs
Top Co-Authors

Avatar

Guillermo J. Ruiz-Delgado

Universidad Popular Autónoma del Estado de Puebla

View shared research outputs
Top Co-Authors

Avatar

Samantha Galindo-Becerra

Universidad Popular Autónoma del Estado de Puebla

View shared research outputs
Top Co-Authors

Avatar

Alejandro Schcolnik-Cabrera

National Autonomous University of Mexico

View shared research outputs
Top Co-Authors

Avatar

David Gómez-Almaguer

Universidad Autónoma de Nuevo León

View shared research outputs
Top Co-Authors

Avatar

Miguel Angel Herrera-Rojas

Universidad Autónoma de Nuevo León

View shared research outputs
Top Co-Authors

Avatar

Elena Soto-Vega

Universidad Popular Autónoma del Estado de Puebla

View shared research outputs
Top Co-Authors

Avatar

Javier Garcés-Eisele

Universidad Popular Autónoma del Estado de Puebla

View shared research outputs
Top Co-Authors

Avatar

Liliana Rivadeneyra-Espinoza

Universidad Popular Autónoma del Estado de Puebla

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge